908 Devices Inc. (MASS)

In November 2025, the company reported Q3 financial results, missing EPS estimates but reaffirming its revenue outlook. In January 2026, strong preliminary Q4 and full-year results led to a stock increase. March 2026 saw the release of Q4 and full-year results, with revenue growth and positive adjusted EBITDA, along with a 2026 revenue outlook. May 2026 brought Q1 results with revenue growth but a significant EPS miss due to acquisition-related charges; the stock gained due to revenue growth and acquisitions. The acquisition of NIRLAB AG in May 2026 expanded narcotics identification capabilities and increased the revenue guidance for 2026. Analyst ratings have varied, with upgrades and downgrades, but the consensus remains a "Moderate Buy." Insider selling has been reported in April-May 2026.

908 Devices, Inc. acknowledges the possibility of seasonality in demand for its products, which may cause fluctuations in operating results. The specific nature and impact of these seasonal variations are not detailed.

908 Devices, Inc. is a commercial-stage technology company specializing in handheld and desktop mass spectrometry (Mass Spec) and Fourier Transform Infrared (FTIR) devices. These devices are used for rapid analysis of unknown materials in life sciences research, bioprocessing, industrial biotech, forensics, and related markets. Key products include the MX908, XplorIR, ThreatID, ProtectIR, VipIR, Rebel, Maverick, Maven, and ZipChip.

908 Devices, Inc. primarily generates revenue from the United States, with additional presence in Europe, the Middle East and Africa, the Americas, and Asia Pacific. The company is headquartered in Burlington, Massachusetts, with facilities in Boston, MA, and R&D sites in Morrisville, NC, and Braunschweig, Germany.

908 Devices, Inc. focuses on providing chemical analysis tools for health, safety, and defense applications, addressing issues like the illicit drug crisis and global security threats. The company emphasizes simplicity, speed, and intelligence in chemical analysis. Its products are used by first responders, defense agencies, and biopharma organizations, suggesting a positive brand image. No significant negative events impacting its brand reputation were found.

908 Devices, Inc. has significant institutional ownership, with 118 institutional owners holding 26,075,676 shares. Major institutional owners include AWM Investment Company, Inc., First Light Asset Management, LLC, ARK Investment Management LLC, BlackRock, Inc., and Vanguard Group Inc, among others. Insider ownership is 9.26%, with recent transactions showing more insider selling than buying.